We caught up with Rohit Aggarwal to discuss the efficacy and safety of IVIg (Octagam 10%) in patients with active dermatomyositis (Clinical Trial Identifier: NCT02728752). The abstract ‘Efficacy and Safety of IVIg (Octagam 10%) in Patients with Active Dermatomyositis. Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial (ProDERM Study)’ (ABSTRACT NUMBER: 0955) was presented at the virtual ACR Convergence 2020, 5-9 November 2020.
Questions
- Could you tell us a little about dermatomyositis and the unmet needs in its treatment? (0:24)
- What is the role of IV immune globulin (IVIG) in the treatment of dermatomyositis? (1:28)
- What were the aims and design of the ProDERM study? (2:39)
- What were the findings of the study in terms of efficacy, safety and tolerability? (3:50)
- What will be the impact of these findings on clinical practice? (6:27)
Disclosures: Dr. Aggarwal has received consulting fees from various pharmaceutical companies including Octapharma, BMS, Mallinckrodt, Pfizer, Janssen, Abbvie, EMD serono, AstraZeneca, Csl Behring, Kezar, Kyverna, Agrenx, Alexion, Q32, Corbus, BI.
Support: Interview and filming supported by Touch Medical Media.
Filmed in coverage of the ACR 2020 Annual Meeting (Virtual).
